Valuation: Acusphere, Inc.

Market Cap 34.65L 30.28L 27.94L 25.76L 48.54L 33Cr 49.62L 3.34Cr 1.31Cr 16Cr 1.3Cr 1.27Cr 56Cr P/E 2006
-1.06x
P/E 2007 -0.49x
Enterprise Value -1.13Cr -98.69L -91.07L -83.94L -1.58Cr -108.75Cr -1.62Cr -11Cr -4.28Cr -53Cr -4.24Cr -4.15Cr -183.36Cr EV / Sales 2006
98,11,030x
EV / Sales 2007 57,44,305x
Free-Float
100%
Yield 2006 *
-
Yield 2007 -
Change 5-day change 1-year change 3-year change Capi.($)
+0.52%+1.19%+14.89%+77.12% 4.82TCr
-0.23%-1.65%+67.15%+109.36% 3.56TCr
+2.03%+1.49%-1.76%+37.04% 1.19TCr
+1.42%+2.52%+19.57%+87.81% 1.18TCr
0.00%+2.87%+34.92%+137.61% 930.92Cr
+3.37%-0.10%+51.64%-4.77% 701.98Cr
-0.75%-0.91%+17.45%+36.14% 690.82Cr
-.--%+0.14% - - 678.76Cr
-0.01%-2.82%+2.36%+201.94% 655.09Cr
Average +0.72%-0.61%+25.78%+85.28% 1.6TCr
Weighted average by Cap. +0.56%-0.68%+30.17%+86.74%

Financials

2006 2007
Net sales 1.78 1.56 1.44 1.32 2.5 171.51 2.55 17.17 6.75 84 6.69 6.54 289.17 2.67 2.33 2.15 1.98 3.74 256.84 3.82 25.71 10.11 125.79 10.02 9.8 433.02
Net income -6.11Cr -5.34Cr -4.93Cr -4.54Cr -8.56Cr -588.3Cr -8.75Cr -59Cr -23Cr -288.12Cr -23Cr -22Cr -991.86Cr -5.37Cr -4.7Cr -4.33Cr -3.99Cr -7.53Cr -517.43Cr -7.69Cr -52Cr -20Cr -253.42Cr -20Cr -20Cr -872.38Cr
Net Debt -5.29Cr -4.62Cr -4.26Cr -3.93Cr -7.41Cr -509.18Cr -7.57Cr -51Cr -20Cr -249.38Cr -20Cr -19Cr -858.48Cr -1.48Cr -1.29Cr -1.19Cr -1.1Cr -2.07Cr -142.12Cr -2.11Cr -14Cr -5.59Cr -70Cr -5.54Cr -5.42Cr -239.62Cr
Logo Acusphere, Inc.
Acusphere, Inc. is a specialty pharmaceutical company. The Company is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The Company's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The Company has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).
Employees
-